Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-10	CN¥63.40	+8.10%	2,565,041
26-07-09	CN¥58.65	-2.28%	2,049,284
26-07-08	CN¥60.02	-0.22%	1,549,700
26-07-07	CN¥60.15	+0.65%	1,468,900
26-07-06	CN¥59.76	+1.39%	2,100,725

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-09			5-day change	1st Jan Change
58.65 ^CNY	-2.28%		-0.76%	-1.71%

Apr. 28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.01B 737M 644M 594M 550M 1.04B 70.31B 1.06B 7.12B 2.79B 34.53B 2.77B 2.71B 120B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	5.33B 785M 686M 633M 586M 1.11B 74.9B 1.13B 7.58B 2.97B 36.78B 2.95B 2.88B 127B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	30.57%	Yield 2024 *	-	Yield 2025	-

Apr. 28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
Apr. 22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
Feb. 26	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
Feb. 24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
Jan. 20	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
Dec. 04	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
25-10-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-12	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
25-09-29	Duorui Pharma Expects Control Change Amid Parents' Plan	MT
25-09-28	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.	CI

1 day	-2.28%
1 week	-0.76%
Current month	+2.88%
1 month	-17.46%
3 months	-7.35%
6 months	+4.98%
Current year	-1.71%

Tibet Duo Rui Pharmaceutical Co., Ltd. Stock

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news : Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	55.81	64.66
1 month	54.89	71.29
Current year	54.89	98.29
1 year	30.51	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	2018-11-30
Chao Li DFI	Director of Finance/CFO	47	2017-04-30
Fen Jin DFI	Director of Finance/CFO	46	2017-11-30

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	2017-11-30
Shao Zhong Zhang BRD	Director/Board Member	70	2020-02-20
Qin Deng BRD	Director/Board Member	58	2020-02-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-2.28%	-0.76%	+102.73%	+140.47%	681M
ELI LILLY AND COMPANY	-2.21%	-0.74%	+50.66%	+162.86%	1,085B
JOHNSON & JOHNSON	-0.42%	-0.35%	+63.87%	+62.00%	624B
ABBVIE INC.	-1.19%	-3.28%	+26.36%	+83.22%	442B
ROCHE HOLDING AG	+0.25%	-1.32%	+27.79%	+26.71%	332B
ASTRAZENECA PLC	-3.91%	-11.00%	+21.08%	+26.39%	277B
NOVARTIS AG	+0.14%	-2.58%	+25.61%	+45.28%	282B
NOVO NORDISK A/S	+0.21%	-1.67%	-29.44%	-39.45%	217B
AMGEN INC.	-0.21%	-1.04%	+20.73%	+61.36%	196B
GILEAD SCIENCES, INC.	-2.25%	+1.67%	+15.05%	+74.10%	167B
Average	-1.29%	-1.73%	+32.45%	+64.29%	362.26B
Weighted average by Cap.	-1.38%	-1.06%	+35.62%	+82.01%

	2024	2025
Net sales	241M 35.41M 30.98M 28.56M 26.43M 50.16M 3.38B 51M 342M 134M 1.66B 133M 130M 5.75B	154M 22.69M 19.85M 18.3M 16.93M 32.14M 2.17B 32.68M 219M 85.92M 1.06B 85.17M 83.33M 3.68B
Net income	-62.67M -9.22M -8.07M -7.44M -6.88M -13.06M -880M -13.28M -89.09M -34.92M -432M -34.62M -33.87M -1.5B	-102M -15.03M -13.15M -12.13M -11.22M -21.3M -1.44B -21.66M -145M -56.94M -705M -56.44M -55.22M -2.44B
Net Debt	135M 19.82M 17.34M 15.99M 14.79M 28.08M 1.89B 28.55M 191M 75.06M 929M 74.4M 72.79M 3.22B	327M 48.08M 42.06M 38.79M 35.89M 68.12M 4.59B 69.25M 464M 182M 2.25B 180M 177M 7.81B